IQVIA (NYSE:IQV) Updates FY 2026 Earnings Guidance

IQVIA (NYSE:IQV) updated its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 12.800-13.000 for the period, compared to the consensus earnings per share estimate of 12.570. The company issued revenue guidance of $17.3 billion-$17.5 billion, compared to the consensus revenue estimate of $17.3 billion.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft set a $240.00 price objective on IQVIA in a report on Thursday, July 9th. Wall Street Zen cut shares of IQVIA from a “buy” rating to a “hold” rating in a report on Saturday, June 27th. Weiss Ratings raised IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. Morgan Stanley restated an “equal weight” rating and set a $200.00 price objective (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. Finally, HSBC reiterated a “buy” rating and issued a $240.00 price objective on shares of IQVIA in a research report on Monday, July 6th. Thirteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average price target of $225.71.

IQVIA Stock Up 2.3%

NYSE IQV opened at $212.76 on Tuesday. IQVIA has a 1-year low of $154.50 and a 1-year high of $247.04. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The stock’s 50 day moving average is $189.02 and its two-hundred day moving average is $186.85. The company has a market capitalization of $35.51 billion, a price-to-earnings ratio of 26.36, a PEG ratio of 1.87 and a beta of 1.20.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating the consensus estimate of $3.03 by $0.12. The business had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities analysts forecast that IQVIA will post 11.57 earnings per share for the current fiscal year.

IQVIA announced that its board has authorized a stock buyback program on Thursday, May 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s board believes its shares are undervalued.

Institutional Investors Weigh In On IQVIA

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Quadrant Capital Group LLC boosted its stake in IQVIA by 1.3% in the fourth quarter. Quadrant Capital Group LLC now owns 4,792 shares of the medical research company’s stock worth $1,080,000 after purchasing an additional 60 shares in the last quarter. Private Advisor Group LLC lifted its position in IQVIA by 1.0% during the 3rd quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock worth $1,163,000 after buying an additional 63 shares in the last quarter. Transamerica Financial Advisors LLC increased its position in IQVIA by 16.7% in the 4th quarter. Transamerica Financial Advisors LLC now owns 495 shares of the medical research company’s stock valued at $112,000 after acquiring an additional 71 shares in the last quarter. E Fund Management Co. Ltd. raised its stake in shares of IQVIA by 3.7% in the second quarter. E Fund Management Co. Ltd. now owns 2,099 shares of the medical research company’s stock worth $331,000 after acquiring an additional 74 shares during the last quarter. Finally, Ancora Advisors LLC grew its stake in shares of IQVIA by 17.9% during the third quarter. Ancora Advisors LLC now owns 521 shares of the medical research company’s stock valued at $99,000 after purchasing an additional 79 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.